HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verlato, G. Articles by Muggeo, M. Search for Related Content PubMed PubMed Citation Articles by Verlato, G. Articles by Muggeo, M. Social Bookmarking                What's this?

Mortality From Site-Specific Malignancies in Type 2 Diabetic Patients From Verona

¹ Unit of Epidemiology and Medical Statistics, University of Verona, Verona, Italy
² Division of Endocrinology and Metabolic Diseases, University of Verona, Verona, Italy

OBJECTIVE— The aim of the present work was to compare mortality from site-specific malignancies in type 2 diabetic patients with those in the general population.

RESEARCH DESIGN AND METHODS— Mortality from site-specific cancers was assessed in a population-based cohort of 7,148 type 2 diabetic patients from Verona (Northern Italy) during a 10-year follow-up (1987–1996) by reviewing death certificates. Standardized mortality ratio (SMR) data were computed using as reference mortality rates in the general population of Verona.

RESULTS— During follow-up, 641 patients (378 men and 263 women) died of malignancies. The most common causes of death among site-specific malignancies were digestive tumors both in men (140 of 378, 37.0%) and women (105 of 263, 39.9%), respiratory tumors in men (103 of 378, 27.2%), and tumors of the reproductive system in women (79 of 263, 30.0%). A slight increase in the overall mortality from malignancies was observed in diabetic patients and achieved statistical significance in women (observed/expected = 1.16, 95% CI 1.02–1.30; P = 0.019) but not in men (observed/expected = 1.07, 0.97–1.19; P = 0.163). Excess mortality from hepatic cancer (SMR = 1.86, 1.44–2.38) was observed in both men and women. In addition, women with diabetes experienced a higher mortality from pancreatic tumors (observed/expected = 1.78, 1.13–2.67) and breast tumors (observed/expected = 1.40, 1.06–1.81). Excess mortality from breast cancer was confined to obese women with diabetes.

CONCLUSIONS— Mortality from site-specific malignancies is different in type 2 diabetic patients than in the general population. Better control of body weight seems necessary to prevent the excess mortality from breast cancer in women.

Abbreviations: SMR, standardized mortality ratio

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. E. Rollison, A. R. Giuliano, T. A. Sellers, C. Laronga, C. Sweeney, B. Risendal, K. B. Baumgartner, T. Byers, and M. L. Slattery Population-based Case-Control Study of Diabetes and Breast Cancer Risk in Hispanic and Non-Hispanic White Women Living in US Southwestern States Am. J. Epidemiol., February 15, 2008; 167(4): 447 - 456. [Abstract] [Full Text] [PDF]

				D. P. Rose, S. M. Haffner, and J. Baillargeon Adiposity, the Metabolic Syndrome, and Breast Cancer in African-American and White American Women Endocr. Rev., December 1, 2007; 28(7): 763 - 777. [Abstract] [Full Text] [PDF]

				F. Xue and K. B Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S. [Abstract] [Full Text] [PDF]

				N Travier, M Jeffreys, N Brewer, C. Wright, C. Cunningham, J Hornell, and N Pearce Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study Ann. Onc., August 1, 2007; 18(8): 1414 - 1419. [Abstract] [Full Text] [PDF]

				L. L. Lipscombe, J. E. Hux, and G. L. Booth Reduced Screening Mammography Among Women With Diabetes Arch Intern Med, October 10, 2005; 165(18): 2090 - 2095. [Abstract] [Full Text] [PDF]

				Z. Suba, J. Barabas, G. Szabo, D. Takacs, and M. Ujpal Increased Prevalence of Diabetes and Obesity in Patients With Salivary Gland Tumors Diabetes Care, January 1, 2005; 28(1): 228 - 228. [Full Text] [PDF]

				Z. T. Bloomgarden Definitions of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin Resistance Syndrome Diabetes Care, March 1, 2004; 27(3): 824 - 830. [Full Text] [PDF]